Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency

计划入组 627 人 · 首次发布于 2009 年 11 月 19 日

Retrospective Observational Safety Effectiveness With Kuvan in hpA

计划入组 26 人 · 首次发布于 2019 年 3 月 6 日

Hyperphenylalaninemia in Cerebral Malaria

计划入组 285 人 · 首次发布于 2006 年 6 月 20 日

hPA-0661

HPA-23

H₆₈N₁₇Na₂O₈₆Sb₉W₂₁

RLYB-211

CENTER FOR RESEARCH ON ENVIRONMENT HEALTH AND POPULATION ACTIVITIES HPA

Nepal

ALMIRALL SPA

Italy

COSMO SPA

Italy

PTC Therapeutics Secures Global Approvals for Sephience in PKU Treatment Across Canada and Japan

PTC Therapeutics' Sephience (sepiapterin) Data Reinforce Broad PKU Benefits, Including Diet Liberalization and Sustained Metabolic Control

Rallybio's RLYB212 Phase 2 Trial for FNAIT Prevention Approved in Europe